"Etoposide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
| Descriptor ID |
D005047
|
| MeSH Number(s) |
D02.455.426.559.847.638.960.675.250 D04.615.638.960.675.250 D09.408.348.275
|
| Concept/Terms |
Etoposide- Etoposide
- Demethyl Epipodophyllotoxin Ethylidine Glucoside
- Eposide
Toposar- Toposar
- Etoposide Teva
- Teva, Etoposide
|
Below are MeSH descriptors whose meaning is more general than "Etoposide".
Below are MeSH descriptors whose meaning is more specific than "Etoposide".
This graph shows the total number of publications written about "Etoposide" by people in this website by year, and whether "Etoposide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 6 | 8 |
| 1996 | 2 | 3 | 5 |
| 1997 | 2 | 2 | 4 |
| 1998 | 0 | 2 | 2 |
| 1999 | 1 | 1 | 2 |
| 2000 | 3 | 4 | 7 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 3 | 3 |
| 2003 | 1 | 5 | 6 |
| 2004 | 0 | 8 | 8 |
| 2005 | 0 | 2 | 2 |
| 2006 | 2 | 1 | 3 |
| 2007 | 2 | 3 | 5 |
| 2008 | 3 | 5 | 8 |
| 2009 | 2 | 7 | 9 |
| 2010 | 2 | 5 | 7 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 4 | 5 |
| 2015 | 0 | 3 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 3 | 3 |
| 2019 | 1 | 3 | 4 |
| 2020 | 2 | 5 | 7 |
| 2021 | 2 | 1 | 3 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 2 | 3 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Etoposide" by people in Profiles.
-
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study. Future Oncol. 2025 May; 21(12):1511-1523.
-
Noncanonical inhibition of topoisomerase II alpha by oxidative stress metabolites. Redox Biol. 2025 Mar; 80:103504.
-
DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
-
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial. Oncologist. 2024 May 03; 29(5):e690-e698.
-
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Clin Cancer Res. 2024 02 16; 30(4):824-835.
-
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Adv. 2023 11 14; 7(21):6381-6394.
-
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer. 2023 12; 186:107418.
-
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022 11 03; 387(18):1649-1660.
-
Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide. J Thorac Oncol. 2022 09; 17(9):1122-1129.
-
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022 04; 7(2):100408.